Novo Nordisk A/S (NYSE:NVO) Trading 0.8% Higher

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) shot up 0.8% during trading on Monday . The company traded as high as $126.05 and last traded at $125.47. 1,071,248 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 4,933,323 shares. The stock had previously closed at $124.51.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NVO shares. UBS Group started coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a "neutral" rating for the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, April 1st. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 price objective for the company. Finally, BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research report on Friday. They issued an "outperform" rating and a $163.00 price objective for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $133.60.

Novo Nordisk A/S Trading Down 0.5 %

The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The business has a 50-day simple moving average of $125.93 and a two-hundred day simple moving average of $109.86. The stock has a market cap of $555.78 billion, a price-to-earnings ratio of 45.79, a P/E/G ratio of 2.07 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, research analysts forecast that Novo Nordisk A/S will post 3.33 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a $0.664 dividend. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. This is an increase from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. Novo Nordisk A/S's dividend payout ratio is presently 49.17%.

Institutional Investors Weigh In On Novo Nordisk A/S

Several large investors have recently made changes to their positions in the stock. IHT Wealth Management LLC raised its stake in Novo Nordisk A/S by 3.5% in the 4th quarter. IHT Wealth Management LLC now owns 2,369 shares of the company's stock valued at $321,000 after acquiring an additional 80 shares during the period. Cravens & Co Advisors LLC raised its stake in Novo Nordisk A/S by 1.0% in the 1st quarter. Cravens & Co Advisors LLC now owns 8,250 shares of the company's stock valued at $1,059,000 after acquiring an additional 85 shares during the period. U.S. Capital Wealth Advisors LLC raised its stake in Novo Nordisk A/S by 0.6% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company's stock valued at $1,595,000 after acquiring an additional 90 shares during the period. Hancock Whitney Corp raised its stake in Novo Nordisk A/S by 4.1% in the 1st quarter. Hancock Whitney Corp now owns 2,342 shares of the company's stock valued at $373,000 after acquiring an additional 92 shares during the period. Finally, Clarius Group LLC raised its stake in Novo Nordisk A/S by 0.5% in the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company's stock valued at $1,914,000 after acquiring an additional 93 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.